Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance

By W. Organization. Pediatria i Medycyna Rodzinna, 2020

1,723 citations recorded by the source corpus.

It is intended for clinicians involved in the care of adult, pregnant, and paediatric patients with or at risk for severe acute respiratory infection (SARI) when infection with the COVID-19 virus is suspected. Considerations for paediatric patients and pregnant women are highlighted throughout the text. It is not meant to replace clinical judgment or specialist consultation but rather to strengthen clinical management of these patients and to provide up-to-date guidance. Best practices for infection prevention and control (IPC), triage and optimized supportive care are included.

Subfields: Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/72df0c5e0afc91a65ae5c4f360bc3d69991f5cc5

Citations in the corpus

• Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations (2020, neutral): “61,66 Table 3 summarises the evidence for some of the more prominent therapies: remdesivir, 67–70 lopinavir–ritonavir, 71–74 chloroquine, 75–77 hydroxychloroquine, 79,80 intra venous immunoglobulin, 81,82 convalescent plasma, 83–85 tocilizumab, 57,86 favipiravir, 87 and traditional Chinese…”
• Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery (2020, neutral): “93% at a rest state; severe respiratory distress; > 50% lesions progression within 24 to 48 h in lung imaging) [11,12].”
• COVID-19: Transmission, prevention, and potential therapeutic opportunities (2020, neutral): “Almost all patients are administered oxygen therapy, and WHO has recommended extracorporeal membrane oxygenation (ECMO) for patients with refractory hypoxemia [175].”